Joel Beatty
Stock Analyst at Baird
(4.33)
# 356
Out of 4,940 analysts
196
Total ratings
42.77%
Success rate
21.76%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COGT Cogent Biosciences | Maintains: Neutral | $7 → $9 | $10.93 | -17.66% | 6 | Jul 8, 2025 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $110 → $145 | $111.67 | +29.85% | 7 | Jun 6, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $24.84 | +24.82% | 4 | May 19, 2025 | |
| NGNE Neurogene | Downgrades: Neutral | $38 → $24 | $20.35 | +17.94% | 3 | May 16, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $8 → $4 | $2.20 | +81.82% | 4 | May 13, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $58 → $50 | $18.90 | +164.55% | 2 | May 13, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $680 | $638.90 | +6.43% | 7 | May 13, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $30 → $29 | $13.92 | +108.33% | 2 | May 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $70 → $66 | $43.30 | +52.42% | 15 | May 7, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $167 → $155 | $110.75 | +39.95% | 4 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $103.96 | +55.83% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $26.54 | +54.48% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $10 | $3.78 | +164.55% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $16 | $10.00 | +60.00% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $16 | $6.46 | +147.87% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $44.37 | +64.53% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $19.68 | +62.60% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $38.75 | +93.55% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $11 | $7.82 | +40.66% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $1.70 | +311.76% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $56.80 | +14.44% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $27.39 | +162.87% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $540 → $240 | $5.04 | +4,661.90% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.36 | +230.88% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $9.65 | +159.07% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $0.31 | +2,783.69% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $12.51 | +123.82% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $2.40 | +566.67% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $2.03 | -38.42% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.70 | +2,488.24% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $17.21 | +237.01% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $22.86 | +5.01% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $11.39 | +58.03% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $2.33 | +157.51% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $46 → $31 | $1.29 | +2,303.10% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $4.28 | +554.21% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $435.00 | -59.77% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $4.19 | +234.13% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $17.94 | +502.01% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $40.84 | +90.99% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $9.75 | +925.64% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $14.94 | +703.21% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $1.42 | +31,590.14% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.85 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $8.03 | +86.80% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $120 | $0.59 | +20,170.27% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $5.54 | +242.96% | 3 | Nov 10, 2017 |
Cogent Biosciences
Jul 8, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $10.93
Upside: -17.66%
e.l.f. Beauty
Jun 6, 2025
Maintains: Outperform
Price Target: $110 → $145
Current: $111.67
Upside: +29.85%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $24.84
Upside: +24.82%
Neurogene
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $20.35
Upside: +17.94%
Editas Medicine
May 13, 2025
Maintains: Outperform
Price Target: $8 → $4
Current: $2.20
Upside: +81.82%
Dianthus Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $58 → $50
Current: $18.90
Upside: +164.55%
argenx SE
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $638.90
Upside: +6.43%
Denali Therapeutics
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $13.92
Upside: +108.33%
PTC Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $43.30
Upside: +52.42%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $167 → $155
Current: $110.75
Upside: +39.95%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $103.96
Upside: +55.83%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $26.54
Upside: +54.48%
Mar 25, 2025
Maintains: Outperform
Price Target: $13 → $10
Current: $3.78
Upside: +164.55%
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $10.00
Upside: +60.00%
Mar 7, 2025
Maintains: Outperform
Price Target: $32 → $16
Current: $6.46
Upside: +147.87%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $44.37
Upside: +64.53%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $19.68
Upside: +62.60%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $38.75
Upside: +93.55%
Nov 18, 2024
Upgrades: Outperform
Price Target: $3 → $11
Current: $7.82
Upside: +40.66%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.70
Upside: +311.76%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $56.80
Upside: +14.44%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $27.39
Upside: +162.87%
May 15, 2024
Maintains: Outperform
Price Target: $540 → $240
Current: $5.04
Upside: +4,661.90%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.36
Upside: +230.88%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $9.65
Upside: +159.07%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $0.31
Upside: +2,783.69%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $12.51
Upside: +123.82%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $2.40
Upside: +566.67%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $2.03
Upside: -38.42%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.70
Upside: +2,488.24%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $17.21
Upside: +237.01%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $22.86
Upside: +5.01%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $11.39
Upside: +58.03%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $2.33
Upside: +157.51%
Jun 1, 2022
Maintains: Outperform
Price Target: $46 → $31
Current: $1.29
Upside: +2,303.10%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $4.28
Upside: +554.21%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $435.00
Upside: -59.77%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $4.19
Upside: +234.13%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $17.94
Upside: +502.01%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $40.84
Upside: +90.99%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $9.75
Upside: +925.64%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $14.94
Upside: +703.21%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $1.42
Upside: +31,590.14%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $1.85
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $8.03
Upside: +86.80%
Aug 17, 2018
Maintains: Neutral
Price Target: $240 → $120
Current: $0.59
Upside: +20,170.27%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $5.54
Upside: +242.96%